SCHEMBL4511620

SCHEMBL4511620

COc1ccc(C2(C(=O)Nc3nnc(C(=O)Nc4ccc(N5CCN(C(C)=O)CC5)cc4)o3)CC2)cc1

nearest known ligand 0.61

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
DGAT1 O75907 7/20 0.61
HPGD P15428 2/20 0.48
MAPT P10636 8/20 0.47
LMNA P02545 1/20 0.47
ALDH1A1 P00352 4/20 0.47
KDM4E B2RXH2 2/20 0.47
RAB9A P51151 3/20 0.46
NPC1 O15118 2/20 0.46
KMT2A Q03164 2/20 0.45
USP2 O75604 1/20 0.45
SMN1; SMN2 Q16637 1/20 0.45
CYP2C9 P11712 1/20 0.45
HIF1A Q16665 1/20 0.45
POLB P06746 1/20 0.45
NR4A1 P22736 1/20 0.45
MCL1 Q07820 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4510050 0.97 DGAT1 (0.67) DGAT1HPGDMAPTLMNAALDH1A1
SCHEMBL4512985 0.90 DGAT1 (0.75) DGAT1HPGDMAPTLMNAALDH1A1
SCHEMBL4517504 0.90 DGAT1 (0.64) DGAT1HPGDMAPTLMNAALDH1A1
SCHEMBL4512056 0.87 DGAT1 (0.68) DGAT1HPGDMAPTLMNAALDH1A1
SCHEMBL4510806 0.87 DGAT1 (0.81) DGAT1HPGDMAPTLMNAALDH1A1
SCHEMBL4506673 0.87 DGAT1 (0.81) DGAT1HPGDMAPTLMNAALDH1A1
SCHEMBL4507546 0.87 DGAT1 (0.67) DGAT1HPGDMAPTLMNAALDH1A1
SCHEMBL4496999 0.86 DGAT1 (0.80) DGAT1HPGDMAPTLMNARAB9A
SCHEMBL4517725 0.86 DGAT1 (0.62) DGAT1HPGDMAPTLMNAALDH1A1
SCHEMBL3545027 0.85 DGAT1 (0.69) DGAT1HPGDMAPTLMNAALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090215779-A1 OXADIAZOLE DERIVATIVES AS DGAT INHIBITORS ASTRAZENECA AB (SE) 2009-08-27 US claimed
EP-1893592-A1 OXADIAZOLE DERIVATIVES AS DGAT INHIBITORS AstraZeneca AB (SE) 2008-03-05 EP claimed
WO-2006134317-A1 OXADIAZOLE DERIVATIVES AS DGAT INHIBITORS ASTRAZENECA AB (SE) 2006-12-21 WO claimed
US-20090215779-A1 OXADIAZOLE DERIVATIVES AS DGAT INHIBITORS ASTRAZENECA AB (SE) 2009-08-27 US disclosed
EP-1893592-A1 OXADIAZOLE DERIVATIVES AS DGAT INHIBITORS AstraZeneca AB (SE) 2008-03-05 EP disclosed
WO-2006134317-A1 OXADIAZOLE DERIVATIVES AS DGAT INHIBITORS ASTRAZENECA AB (SE) 2006-12-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090215779-A1 OXADIAZOLE DERIVATIVES AS DGAT INHIBITORS DGAT2, GPR119, DGAT1 DGAT1 3/4885HPGD 1522/4885MAPT 2561/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.